celecoxib,ipilimumab,nivolumab
bms,pfizer
['rectal', 'biomarker', 'niche,(-niche 2),(-niche-2),(-niche2)', 'colorectal']
results from the niche trial led by show remarkable pathological responses to neoadjuvant combination #immunotherapy in early-stage #colorectalcancer patients and uncover potential biomarkers of response #aacr23 #earlyphasetrial 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.